Holen Sie sich die Stockscreener-App
0.5955
3.05%
-0.0204
Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten
What drives Calidi Biotherapeutics Inc. stock priceRapid-fire capital growth - Jammu Links News
Calidi Biotherapeutics Inc. Stock Analysis and ForecastOutstanding growth strategies - Jammu Links News
What analysts say about Calidi Biotherapeutics Inc. stockBreakout stock performance - Jammu Links News
What risks could impact Calidi Biotherapeutics Inc. stock performanceFree Stock Trading Community - Newser
Is Calidi Biotherapeutics Inc. a good long term investmentAccelerated wealth building - Jammu Links News
What makes Calidi Biotherapeutics Inc. stock price move sharplyFree Professional Portfolio Management - Newser
Why Calidi Biotherapeutics Inc. stock attracts strong analyst attentionFree Best Performing Stock Suggestions - Newser
How Calidi Biotherapeutics Inc. stock performs during market volatilityMarket Beating Strategy - Newser
Calidi Biotherapeutics Inc Inc. (CLDI) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Calidi Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks
Calidi Biotherapeutics Plummets 27%—Can Biotech Breakthroughs Stem the Slide? - AInvest
Calidi Biotherapeutics Plunges 4.81% Amid Bridge Financing - AInvest
Top Penny Stocks To Add to Your Watchlist – July 9th - Defense World
Calidi Biotherapeutics Announces Inducement Offer Agreement - TipRanks
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Calidi Biotherapeutics: Redefining Cancer Treatment with Breakthrough Virotherapy - AInvest
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment - The Manila Times
Breakthrough Cancer Treatment: Calidi's New Genetic Platform Targets Both Primary and Metastatic Tumors - Stock Titan
Calidi Biotherapeutics Cashes In On Warrant Agreement - Finimize
Calidi Biotherapeutics secures $4.6 million through warrant exercise - Investing.com Australia
Calidi Biotherapeutics secures $4.6 million through warrant exercise By Investing.com - Investing.com Nigeria
Calidi Biotherapeutics to Raise $4.6 Million Through Warrant Exercise Agreement - MarketScreener
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers - The Malaysian Reserve
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds - The Manila Times
Clinical-Stage Biotech Calidi Raises $4.6M in Fresh Capital: Accelerates Targeted Therapy Programs - Stock Titan
Crude Oil Moves Higher; RxSight Shares Plunge - Benzinga
Dow Jumps 200 Points; US Wholesale Inventories Fall 0.3% In May - Benzinga
Calidi Biotherapeutics Stock Soars 174.93% on Precision Medicine Hype - AInvest
Calidi Biotherapeutics Soars 119.7% on Cancer Trial News - AInvest
Calidi Biotherapeutics Stock Jumps 39% After Hours — What's Going On - Benzinga
Revolutionary Cancer Treatment: How Engineered Viruses Could Transform Genetic Medicine Delivery - Stock Titan
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs – Company AnnouncementFT.com - Financial Times
Calidi Biotherapeutics (CLDI): A Breakthrough in Systemic Virotherapy and the $564B Oncology Opportunity - AInvest
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of… - Informazione.it
Calidi Biotherapeutics (NYSE:CLDI) Shares Up 5.6% – Still a Buy? - Defense World
CLDI SEC FilingsCalidi Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Calidi Biotherapeutics Granted Patent for Cell-Based Oncolytic Virus Immunotherapy for Cancer Treatment - ACCESS Newswire
Certain Warrants of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-JUN-2025. - MarketScreener
Calidi Biotherapeutics Announces Shareholder Letter from CEO - The Manila Times
Millennium Management LLC Increases Stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma, PhD, as CEO to Lead Next Growth Phase - citybuzz -
Jane Street Group LLC Takes Position in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World
Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025 - citybuzz -
Calidi Biotherapeutics Presents systemic oncolytic platform - GlobeNewswire
Calidi Biotherapeutics (CLDI) Showcases Innovative CLD-401 Thera - GuruFocus
Revolutionary Cancer Treatment Breakthrough: Calidi's New Systemic Delivery Platform Wows ASCO Conference - Stock Titan
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting - The Manila Times
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - The Globe and Mail
Calidi Biotherapeutics (NYSE:CLDI) Shares Down 5.3% – Time to Sell? - Defense World
Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance
0.86%
0.10%
Kapitalisierung:
|
Volumen (24h):